Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

BACKGROUND: Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerability. However, little is known about possible predictors, dose dependence and ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Schenk, Hannah, Holle, Dagny, Nsaka, Michael, Kleinschnitz, Christoph, Glas, Martin, Scheffler, Armin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092816/
https://www.ncbi.nlm.nih.gov/pubmed/35538414
http://dx.doi.org/10.1186/s10194-022-01426-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092816/
https://www.ncbi.nlm.nih.gov/pubmed/35538414
http://dx.doi.org/10.1186/s10194-022-01426-8

Ejemplares similares